Drug Trial Radar · NCT03988439
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Mar 24, 2021
Primary completion
Feb 6, 2026
Study completion Feb 6, 2026
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
IDP-118 LotionDrug
Topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: : Maximum Observed Drug (Halobetasol Propionate, Tazarotene, or Tazarotenic Acid) Concentration in Plasma (Cmax) of IDP-118 Lotion AnalytesTime frame: 0 (predose), 1, 2, 4, 8, 12, and 24 hours postdose
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Bausch Site 7
Doral, Florida
Bausch Site 11
Miami, Florida
Bausch Site 3
Louisville, Kentucky
Bausch Site 6
Saint Joseph, Missouri
Bausch Site 1
Henderson, Nevada
Bausch Site 5
San Antonio, Texas
Bausch Site 4
Murray, Utah
Bausch Site 12
Santo Domingo, Dominican Republic
Bausch Site 2
Panama City, Panama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.